Influence of Cardiopulmonary Bypass on Nitroglycerin Clearance

The effect of cardiopulmonary bypass on the clearance of nitroglycerin (NTG) was studied in seven patients scheduled for coronary artery bypass graft surgery. Intravenous NTG was administered through nonadsorbing tubing at a starting dosage of 5–10 μg/min and was adjusted as needed. Blood samples we...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical pharmacology 1986-03, Vol.26 (3), p.165-168
Hauptverfasser: Dasta, Joseph F., Weber, Robert J., Wu, Lei Shu, Sokoloski, Theodore D., Kakos, Gerard S., Smith, Douglas F., Howie, Michael B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 168
container_issue 3
container_start_page 165
container_title Journal of clinical pharmacology
container_volume 26
creator Dasta, Joseph F.
Weber, Robert J.
Wu, Lei Shu
Sokoloski, Theodore D.
Kakos, Gerard S.
Smith, Douglas F.
Howie, Michael B.
description The effect of cardiopulmonary bypass on the clearance of nitroglycerin (NTG) was studied in seven patients scheduled for coronary artery bypass graft surgery. Intravenous NTG was administered through nonadsorbing tubing at a starting dosage of 5–10 μg/min and was adjusted as needed. Blood samples were obtained from the radial artery and antecubital vein before bypass and from the arterial outlet of the oxygenator during bypass at least 30 minutes apart during a constant dosage or at least 30 minutes after a dosage change. Serum concentrations were analyzed for NTG by gas chromatography. Venous NTG concentrations were always lower than concurrent arterial concentrations, with an average arteriovenous extraction of 67.2%. Serum concentrations of NTG were generally within the range associated with a therapeutic response in congestive heart failure patients. Consistent with other reports, NTG concentrations varied widely among patients and considerable intrasubject fluctuations in drug concentrations were seen. The mean ± SD apparent clearance of NTG before bypass of 0.044 ± 0.02 L/kg/min increased 20% to 0.052 ± 0.02 L/kg/min during bypass (P = .05). These results suggest that cardiopulmonary bypass increases the clearance of NTG; however, the magnitude appears to be small and only partially explains the reported increased dosage needed during cardiopulmonary bypass.
doi_str_mv 10.1002/j.1552-4604.1986.tb02928.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76765511</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76765511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4388-992763ccc0f9b82aa70a71eb43b1e2d71b37727d349488572538ff7319b12c33</originalsourceid><addsrcrecordid>eNqVkF1LwzAUhoMoc05_glBEvGvNR9skXoha3JyMKTLwMqRZKp1ZW5MW139vy8ruvTqB9-OcPABcIRggCPHtJkBRhP0whmGAOIuDOoWYYxbsjsD4IB2DMYQc-ZhCeArOnNtAiOIwQiMwIpBhHqIxuJ8XmWl0obRXZl4i7Tovq8Zsy0La1ntqK-mcVxbeMq9t-WVapW1eeInR0soudA5OMmmcvhjmBKymz6vkxV-8zebJ48JXIWHM5xzTmCilYMZThqWkUFKk05CkSOM1RSmhFNM1CXnIWERxRFiWUYJ4irAiZAJu9rWVLX8a7WqxzZ3SxshCl40TNKZxFCHUGe_2RmVL56zORGXzbfcVgaDo2YmN6AGJHpDo2YmBndh14cthS5Nu9foQHWB1-vWgS6ekyXoCuTvYGKWE8f7Yh73tNze6_ccB4jV5f-mfXYW_r8hdrXeHCmm_RUwJjcTnciaS1XT6MZtxMSV_9AaZ6g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76765511</pqid></control><display><type>article</type><title>Influence of Cardiopulmonary Bypass on Nitroglycerin Clearance</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Dasta, Joseph F. ; Weber, Robert J. ; Wu, Lei Shu ; Sokoloski, Theodore D. ; Kakos, Gerard S. ; Smith, Douglas F. ; Howie, Michael B.</creator><creatorcontrib>Dasta, Joseph F. ; Weber, Robert J. ; Wu, Lei Shu ; Sokoloski, Theodore D. ; Kakos, Gerard S. ; Smith, Douglas F. ; Howie, Michael B.</creatorcontrib><description>The effect of cardiopulmonary bypass on the clearance of nitroglycerin (NTG) was studied in seven patients scheduled for coronary artery bypass graft surgery. Intravenous NTG was administered through nonadsorbing tubing at a starting dosage of 5–10 μg/min and was adjusted as needed. Blood samples were obtained from the radial artery and antecubital vein before bypass and from the arterial outlet of the oxygenator during bypass at least 30 minutes apart during a constant dosage or at least 30 minutes after a dosage change. Serum concentrations were analyzed for NTG by gas chromatography. Venous NTG concentrations were always lower than concurrent arterial concentrations, with an average arteriovenous extraction of 67.2%. Serum concentrations of NTG were generally within the range associated with a therapeutic response in congestive heart failure patients. Consistent with other reports, NTG concentrations varied widely among patients and considerable intrasubject fluctuations in drug concentrations were seen. The mean ± SD apparent clearance of NTG before bypass of 0.044 ± 0.02 L/kg/min increased 20% to 0.052 ± 0.02 L/kg/min during bypass (P = .05). These results suggest that cardiopulmonary bypass increases the clearance of NTG; however, the magnitude appears to be small and only partially explains the reported increased dosage needed during cardiopulmonary bypass.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1002/j.1552-4604.1986.tb02928.x</identifier><identifier>PMID: 3082941</identifier><identifier>CODEN: JCPCBR</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Antianginal agents. Coronary vasodilator agents ; Biological and medical sciences ; Cardiopulmonary Bypass ; Cardiovascular system ; Female ; Humans ; Infusions, Parenteral ; Kinetics ; Male ; Medical sciences ; Metabolic Clearance Rate ; Middle Aged ; Nitroglycerin - administration &amp; dosage ; Nitroglycerin - blood ; Pharmacology. Drug treatments</subject><ispartof>Journal of clinical pharmacology, 1986-03, Vol.26 (3), p.165-168</ispartof><rights>1986 American College of Clinical Pharmacology</rights><rights>1986 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4388-992763ccc0f9b82aa70a71eb43b1e2d71b37727d349488572538ff7319b12c33</citedby><cites>FETCH-LOGICAL-c4388-992763ccc0f9b82aa70a71eb43b1e2d71b37727d349488572538ff7319b12c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fj.1552-4604.1986.tb02928.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fj.1552-4604.1986.tb02928.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=8773893$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3082941$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dasta, Joseph F.</creatorcontrib><creatorcontrib>Weber, Robert J.</creatorcontrib><creatorcontrib>Wu, Lei Shu</creatorcontrib><creatorcontrib>Sokoloski, Theodore D.</creatorcontrib><creatorcontrib>Kakos, Gerard S.</creatorcontrib><creatorcontrib>Smith, Douglas F.</creatorcontrib><creatorcontrib>Howie, Michael B.</creatorcontrib><title>Influence of Cardiopulmonary Bypass on Nitroglycerin Clearance</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>The effect of cardiopulmonary bypass on the clearance of nitroglycerin (NTG) was studied in seven patients scheduled for coronary artery bypass graft surgery. Intravenous NTG was administered through nonadsorbing tubing at a starting dosage of 5–10 μg/min and was adjusted as needed. Blood samples were obtained from the radial artery and antecubital vein before bypass and from the arterial outlet of the oxygenator during bypass at least 30 minutes apart during a constant dosage or at least 30 minutes after a dosage change. Serum concentrations were analyzed for NTG by gas chromatography. Venous NTG concentrations were always lower than concurrent arterial concentrations, with an average arteriovenous extraction of 67.2%. Serum concentrations of NTG were generally within the range associated with a therapeutic response in congestive heart failure patients. Consistent with other reports, NTG concentrations varied widely among patients and considerable intrasubject fluctuations in drug concentrations were seen. The mean ± SD apparent clearance of NTG before bypass of 0.044 ± 0.02 L/kg/min increased 20% to 0.052 ± 0.02 L/kg/min during bypass (P = .05). These results suggest that cardiopulmonary bypass increases the clearance of NTG; however, the magnitude appears to be small and only partially explains the reported increased dosage needed during cardiopulmonary bypass.</description><subject>Adult</subject><subject>Antianginal agents. Coronary vasodilator agents</subject><subject>Biological and medical sciences</subject><subject>Cardiopulmonary Bypass</subject><subject>Cardiovascular system</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Parenteral</subject><subject>Kinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic Clearance Rate</subject><subject>Middle Aged</subject><subject>Nitroglycerin - administration &amp; dosage</subject><subject>Nitroglycerin - blood</subject><subject>Pharmacology. Drug treatments</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkF1LwzAUhoMoc05_glBEvGvNR9skXoha3JyMKTLwMqRZKp1ZW5MW139vy8ruvTqB9-OcPABcIRggCPHtJkBRhP0whmGAOIuDOoWYYxbsjsD4IB2DMYQc-ZhCeArOnNtAiOIwQiMwIpBhHqIxuJ8XmWl0obRXZl4i7Tovq8Zsy0La1ntqK-mcVxbeMq9t-WVapW1eeInR0soudA5OMmmcvhjmBKymz6vkxV-8zebJ48JXIWHM5xzTmCilYMZThqWkUFKk05CkSOM1RSmhFNM1CXnIWERxRFiWUYJ4irAiZAJu9rWVLX8a7WqxzZ3SxshCl40TNKZxFCHUGe_2RmVL56zORGXzbfcVgaDo2YmN6AGJHpDo2YmBndh14cthS5Nu9foQHWB1-vWgS6ekyXoCuTvYGKWE8f7Yh73tNze6_ccB4jV5f-mfXYW_r8hdrXeHCmm_RUwJjcTnciaS1XT6MZtxMSV_9AaZ6g</recordid><startdate>198603</startdate><enddate>198603</enddate><creator>Dasta, Joseph F.</creator><creator>Weber, Robert J.</creator><creator>Wu, Lei Shu</creator><creator>Sokoloski, Theodore D.</creator><creator>Kakos, Gerard S.</creator><creator>Smith, Douglas F.</creator><creator>Howie, Michael B.</creator><general>Blackwell Publishing Ltd</general><general>Sage Science</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198603</creationdate><title>Influence of Cardiopulmonary Bypass on Nitroglycerin Clearance</title><author>Dasta, Joseph F. ; Weber, Robert J. ; Wu, Lei Shu ; Sokoloski, Theodore D. ; Kakos, Gerard S. ; Smith, Douglas F. ; Howie, Michael B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4388-992763ccc0f9b82aa70a71eb43b1e2d71b37727d349488572538ff7319b12c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Adult</topic><topic>Antianginal agents. Coronary vasodilator agents</topic><topic>Biological and medical sciences</topic><topic>Cardiopulmonary Bypass</topic><topic>Cardiovascular system</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Parenteral</topic><topic>Kinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic Clearance Rate</topic><topic>Middle Aged</topic><topic>Nitroglycerin - administration &amp; dosage</topic><topic>Nitroglycerin - blood</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dasta, Joseph F.</creatorcontrib><creatorcontrib>Weber, Robert J.</creatorcontrib><creatorcontrib>Wu, Lei Shu</creatorcontrib><creatorcontrib>Sokoloski, Theodore D.</creatorcontrib><creatorcontrib>Kakos, Gerard S.</creatorcontrib><creatorcontrib>Smith, Douglas F.</creatorcontrib><creatorcontrib>Howie, Michael B.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dasta, Joseph F.</au><au>Weber, Robert J.</au><au>Wu, Lei Shu</au><au>Sokoloski, Theodore D.</au><au>Kakos, Gerard S.</au><au>Smith, Douglas F.</au><au>Howie, Michael B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of Cardiopulmonary Bypass on Nitroglycerin Clearance</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>1986-03</date><risdate>1986</risdate><volume>26</volume><issue>3</issue><spage>165</spage><epage>168</epage><pages>165-168</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><coden>JCPCBR</coden><abstract>The effect of cardiopulmonary bypass on the clearance of nitroglycerin (NTG) was studied in seven patients scheduled for coronary artery bypass graft surgery. Intravenous NTG was administered through nonadsorbing tubing at a starting dosage of 5–10 μg/min and was adjusted as needed. Blood samples were obtained from the radial artery and antecubital vein before bypass and from the arterial outlet of the oxygenator during bypass at least 30 minutes apart during a constant dosage or at least 30 minutes after a dosage change. Serum concentrations were analyzed for NTG by gas chromatography. Venous NTG concentrations were always lower than concurrent arterial concentrations, with an average arteriovenous extraction of 67.2%. Serum concentrations of NTG were generally within the range associated with a therapeutic response in congestive heart failure patients. Consistent with other reports, NTG concentrations varied widely among patients and considerable intrasubject fluctuations in drug concentrations were seen. The mean ± SD apparent clearance of NTG before bypass of 0.044 ± 0.02 L/kg/min increased 20% to 0.052 ± 0.02 L/kg/min during bypass (P = .05). These results suggest that cardiopulmonary bypass increases the clearance of NTG; however, the magnitude appears to be small and only partially explains the reported increased dosage needed during cardiopulmonary bypass.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>3082941</pmid><doi>10.1002/j.1552-4604.1986.tb02928.x</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0091-2700
ispartof Journal of clinical pharmacology, 1986-03, Vol.26 (3), p.165-168
issn 0091-2700
1552-4604
language eng
recordid cdi_proquest_miscellaneous_76765511
source MEDLINE; Wiley Online Library
subjects Adult
Antianginal agents. Coronary vasodilator agents
Biological and medical sciences
Cardiopulmonary Bypass
Cardiovascular system
Female
Humans
Infusions, Parenteral
Kinetics
Male
Medical sciences
Metabolic Clearance Rate
Middle Aged
Nitroglycerin - administration & dosage
Nitroglycerin - blood
Pharmacology. Drug treatments
title Influence of Cardiopulmonary Bypass on Nitroglycerin Clearance
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T03%3A22%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20Cardiopulmonary%20Bypass%20on%20Nitroglycerin%20Clearance&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Dasta,%20Joseph%20F.&rft.date=1986-03&rft.volume=26&rft.issue=3&rft.spage=165&rft.epage=168&rft.pages=165-168&rft.issn=0091-2700&rft.eissn=1552-4604&rft.coden=JCPCBR&rft_id=info:doi/10.1002/j.1552-4604.1986.tb02928.x&rft_dat=%3Cproquest_cross%3E76765511%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76765511&rft_id=info:pmid/3082941&rfr_iscdi=true